GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » Cyclically Adjusted PB Ratio

Kamada (Kamada) Cyclically Adjusted PB Ratio : 1.40 (As of Jun. 08, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Kamada Cyclically Adjusted PB Ratio?

As of today (2024-06-08), Kamada's current share price is $5.06. Kamada's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.62. Kamada's Cyclically Adjusted PB Ratio for today is 1.40.

The historical rank and industry rank for Kamada's Cyclically Adjusted PB Ratio or its related term are showing as below:

KMDA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.15   Med: 1.61   Max: 2.59
Current: 1.45

During the past years, Kamada's highest Cyclically Adjusted PB Ratio was 2.59. The lowest was 1.15. And the median was 1.61.

KMDA's Cyclically Adjusted PB Ratio is ranked better than
60.78% of 742 companies
in the Drug Manufacturers industry
Industry Median: 1.875 vs KMDA: 1.45

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Kamada's adjusted book value per share data for the three months ended in Mar. 2024 was $4.289. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.62 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Kamada Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Kamada's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Cyclically Adjusted PB Ratio Chart

Kamada Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.26 1.91 1.13 1.72

Kamada Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 1.54 1.59 1.72 1.55

Competitive Comparison of Kamada's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kamada's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kamada's Cyclically Adjusted PB Ratio falls into.



Kamada Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Kamada's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=5.06/3.62
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kamada's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Kamada's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.289/131.7762*131.7762
=4.289

Current CPI (Mar. 2024) = 131.7762.

Kamada Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.243 100.560 2.939
201409 2.184 100.428 2.866
201412 2.235 99.070 2.973
201503 2.099 99.621 2.777
201506 2.084 100.684 2.728
201509 1.953 100.392 2.564
201512 1.991 99.792 2.629
201603 1.946 100.470 2.552
201606 1.905 101.688 2.469
201609 1.886 101.861 2.440
201612 1.831 101.863 2.369
201703 1.736 102.862 2.224
201706 1.876 103.349 2.392
201709 2.080 104.136 2.632
201712 2.223 104.011 2.816
201803 2.238 105.290 2.801
201806 2.382 106.317 2.952
201809 2.331 106.507 2.884
201812 2.789 105.998 3.467
201903 2.915 107.251 3.582
201906 3.077 108.070 3.752
201909 3.212 108.329 3.907
201912 3.353 108.420 4.075
202003 3.724 108.902 4.506
202006 3.795 108.767 4.598
202009 3.951 109.815 4.741
202012 3.993 109.897 4.788
202103 4.050 111.754 4.776
202106 4.071 114.631 4.680
202109 4.055 115.734 4.617
202112 3.947 117.630 4.422
202203 3.910 121.301 4.248
202206 3.830 125.017 4.037
202209 3.849 125.227 4.050
202212 3.926 125.222 4.131
202303 3.899 127.348 4.035
202306 3.942 128.729 4.035
202309 4.148 129.860 4.209
202312 4.245 129.419 4.322
202403 4.289 131.776 4.289

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kamada  (NAS:KMDA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Kamada Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Kamada's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kamada (Kamada) Business Description

Industry
Traded in Other Exchanges
Address
2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.